- Business Wire•9 minutes agoPfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration
Pfizer Inc. today announced that a Biologics License Application for inotuzumab ozogamicin has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration .
- Reuters•6 hours ago
Kraft Heinz's dropped bid to buy Unilever is the third-largest M&A deal to collapse, according to Thomson Reuters data, adding to a recent run of failures that highlights the appetite for the pursuit of audacious mega-mergers. The abrupt U-turn by U.S. foods giant Kraft at the weekend pushed the value of deals withdrawn this year to $205.2 billion, compared with $53.6 billion at the same point in 2016.
- Motley Fool•2 days ago
Why Pfizer is a smart stock to buy for billionaires and wanna-be billionaires alike.
PFE : Summary for Pfizer, Inc. - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||33.53 - 33.89|
|52 Week Range||28.74 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||28.66|
|Dividend & Yield||1.28 (3.81%)|
|1y Target Est||N/A|